13F-HR: Johnson & Johnson 13F Holdings — June 30, 2026

Institutional Holdings Report (13F)


Johnson & Johnson reported 15 holdings worth $798.7M for the period ended June 30, 2026.

Summary

  • Johnson & Johnson reported 15 holdings worth $798.7M as of June 30, 2026.
  • PROTAGONIST THERAPEUTICS INC — $300.2M (37.59%), 2,449,183 SH.
  • NANOBIOTIX — $212.0M (26.55%), 5,623,816 SH.
  • MEIRAGTX HLDGS PLC — $89.7M (11.23%), 6,641,064 SH.
  • RAPPORT THERAPEUTICS INC — $74.4M (9.31%), 1,784,517 SH.
  • CONTINEUM THERAPEUTICS INC — $32.4M (4.06%), 1,979,173 SH.

Top Holdings

Johnson & Johnson · 15 positions · $798.7M total · as of June 30, 2026
IssuerValue% Port.Shares
PROTAGONIST THERAPEUTICS INC$300.2M37.59%2,449,183
NANOBIOTIX$212.0M26.55%5,623,816
MEIRAGTX HLDGS PLC$89.7M11.23%6,641,064
RAPPORT THERAPEUTICS INC$74.4M9.31%1,784,517
CONTINEUM THERAPEUTICS INC$32.4M4.06%1,979,173
LEGEND BIOTECH CORP$23.5M2.95%814,586
CVRX INC$20.7M2.59%4,024,861
XENCOR INC$12.0M1.51%748,062
CEREBRAS SYSTEMS INC$11.8M1.48%53,586
FATE THERAPEUTICS INC$9.1M1.14%3,379,064

Keywords

13F, institutional holdings, Johnson & Johnson, PROTAGONIST THERAPEUTICS INC, NANOBIOTIX, MEIRAGTX HLDGS PLC, RAPPORT THERAPEUTICS INC, CONTINEUM THERAPEUTICS INC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.